CSF tau and tau/Aβ42 predict cognitive decline in Parkinson's disease

Parkinsonism and Related Disorders

Volumn 21, Issue 3, 2015, Pages 271-276

  Liu, Changqin ^a,b   Cholerton, Brenna ^a,c   Shi, Min ^a   Ginghina, Carmen ^a   Cain, Kevin C ^d   Auinger, Peggy ^e   Zhang, Jing ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b THE FIRST AFFILIATED HOSPITAL OF XIAMEN UNIVERSITY   (China)

^c VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

^e UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

Biomarkers; Cerebrospinal fluid; Cognition; Neuropsychological tests; Parkinson disease; Tau proteins

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; APOLIPOPROTEIN E; LEVODOPA; PHOSPHOPROTEIN; TAU PROTEIN; ALPHA TOCOPHEROL; AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); ANTIOXIDANT; MONOAMINE OXIDASE INHIBITOR; PEPTIDE FRAGMENT; SELEGILINE;

ADULT; APOE GENE; ARTICLE; COGNITION; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; EXECUTIVE FUNCTION; FEMALE; GENE; GENOTYPE; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MAPT GENE; MEMORY; MENTAL DETERIORATION; PARKINSON DISEASE; PHENOTYPE; PREDICTION; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN PHOSPHORYLATION; AGED; CEREBROSPINAL FLUID; CLINICAL TRIAL; COGNITION DISORDERS; COHORT ANALYSIS; COMPLICATION; GENETICS; MIDDLE AGED; MULTICENTER STUDY; NEUROPSYCHOLOGICAL TEST; PREDICTIVE VALUE; RANDOMIZED CONTROLLED TRIAL; SEVERITY OF ILLNESS INDEX; STATISTICAL MODEL; TIME FACTOR;

ADULT; AGED; AMYLOID BETA-PEPTIDES; ANTIOXIDANTS; APOLIPOPROTEINS E; COGNITION DISORDERS; COHORT STUDIES; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; LINEAR MODELS; MALE; MIDDLE AGED; MONOAMINE OXIDASE INHIBITORS; NEUROPSYCHOLOGICAL TESTS; PARKINSON DISEASE; PEPTIDE FRAGMENTS; PREDICTIVE VALUE OF TESTS; SELEGILINE; SEVERITY OF ILLNESS INDEX; TAU PROTEINS; TIME FACTORS; VITAMIN E;

EID: 84923225980     PISSN: 13538020     EISSN: 18735126     Source Type: Journal    
DOI: 10.1016/j.parkreldis.2014.12.027     Document Type: Article

References (29)

1. Alves G., Bronnick K., Aarsland D., Blennow K., Zetterberg H., Ballard C., et al. CSF amyloid-beta and tau proteins, and cognitive performance, in early and untreated Parkinson's disease: the Norwegian ParkWest study. JNeurol Neurosurg Psychiatry 2010, 81:1080-1086.
2. Montine T.J., Shi M., Quinn J.F., Peskind E.R., Craft S., Ginghina C., et al. CSF Abeta(42) and tau in Parkinson's disease with cognitive impairment. Mov Disord 2010, 25:2682-2685.
3. Shi M., Bradner J., Hancock A.M., Chung K.A., Quinn J.F., Peskind E.R., et al. Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression. Ann Neurol 2011, 69:570-580.
4. Mollenhauer B., Trenkwalder C., von Ahsen N., Bibl M., Steinacker P., Brechlin P., et al. Beta-amlyoid 1-42 and tau-protein in cerebrospinal fluid of patients with Parkinson's disease dementia. Dement Geriatr Cogn Disord 2006, 22:200-208.
5. Compta Y., Marti M.J., Ibarretxe-Bilbao N., Junque C., Valldeoriola F., Munoz E., et al. Cerebrospinal tau, phospho-tau, and beta-amyloid and neuropsychological functions in Parkinson's disease. Mov Disord 2009, 24:2203-2210.
6. Leverenz J.B., Watson G.S., Shofer J., Zabetian C.P., Zhang J., Montine T.J. Cerebrospinal fluid biomarkers and cognitive performance in non-demented patients with Parkinson's disease. Parkinsonism Relat Disord 2011, 17:61-64.
7. Siderowf A., Xie S.X., Hurtig H., Weintraub D., Duda J., Chen-Plotkin A., et al. CSF amyloid {beta} 1-42 predicts cognitive decline in Parkinson disease. Neurology 2010, 75:1055-1061.
8. Zhang J., Mattison H.A., Liu C., Ginghina C., Auinger P., McDermott M.P., et al. Longitudinal assessment of tau and amyloid beta in cerebrospinal fluid of Parkinson disease. Acta Neuropathol 2013, 126:671-682.
9. DATATOP: a multicenter controlled clinical trial in early Parkinson's disease. Arch Neurol 1989, 46:1052-1060. ParkinsonStudyGroup.
10. Shoulson I. Deprenyl and tocopherol antioxidative therapy of parkinsonism (DATATOP). Parkinson Study Group. Acta Neurol Scand Suppl 1989, 126:171-175.
11. Alcalay R.N., Caccappolo E., Mejia-Santana H., Tang M.X., Rosado L., Ross B.M., et al. Frequency of known mutations in early-onset Parkinson disease: implication for genetic counseling: the consortium on risk for early onset Parkinson disease study. Arch Neurol 2010, 67:1116-1122.
12. Marder K.S., Tang M.X., Mejia-Santana H., Rosado L., Louis E.D., Comella C.L., et al. Predictors of parkin mutations in early-onset Parkinson disease: the consortium on risk for early-onset Parkinson disease study. Arch Neurol 2010, 67:731-738.
13. Buschke H., Fuld P.A. Evaluating storage, retention, and retrieval in disordered memory and learning. Neurology 1974, 24:1019-1025.
14. Smith A. Symbol digit modalities test 1973, Western Psychological Services, Los Angeles, CA.
15. Folstein M.F., Folstein S.E., McHugh P.R. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. JPsychiatr Res 1975, 12:189-198.
16. Hong Z., Shi M., Chung K.A., Quinn J.F., Peskind E.R., Galasko D., et al. DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease. Brain 2010, 133:713-726.
17. Aasly J.O., Shi M., Sossi V., Stewart T., Johansen K.K., Wszolek Z.K., et al. Cerebrospinal fluid amyloid beta and tau in LRRK2 mutation carriers. Neurology 2012, 78:55-61.
18. Ghebranious N., Ivacic L., Mallum J., Dokken C. Detection of ApoE E2, E3 and E4 alleles using MALDI-TOF mass spectrometry and the homogeneous mass-extend technology. Nucleic Acids Res 2005, 33:e149.
19. Jankovic J., McDermott M., Carter J., Gauthier S., Goetz C., Golbe L., et al. Variable expression of Parkinson's disease: a base-line analysis of the DATATOP cohort. The Parkinson Study Group. Neurology 1990, 40:1529-1534.
20. Odekerken V.J., van Laar T., Staal M.J., Mosch A., Hoffmann C.F., Nijssen P.C., et al. Subthalamic nucleus versus globus pallidus bilateral deep brain stimulation for advanced Parkinson's disease (NSTAPS study): a randomised controlled trial. Lancet Neurol 2013, 12:37-44.
21. Kang J., Caspell C., Coffey C., Taylor P., Frasier M., Marek K., et al. Association between CSF biomarkers and clinical phenotype of early Parkinson's disease in the Parkinson's Progression Marker Initiative (PPMI). Mov Disord 2012, 27(Suppl.1):S34-S35.
22. Shi M., Zhang J. CSF alpha-synuclein, tau, and amyloid beta in Parkinson's disease. Lancet Neurol 2011, 10:681. author's reply 681-683.
23. Lei P., Ayton S., Finkelstein D.I., Spoerri L., Ciccotosto G.D., Wright D.K., et al. Tau deficiency induces parkinsonism with dementia by impairing APP-mediated iron export. Nat Med 2012, 18:291-295.
24. Kang J.H., Irwin D.J., Chen-Plotkin A.S., Siderowf A., Caspell C., Coffey C.S., et al. Association of cerebrospinal fluid beta-amyloid 1-42, T-tau, P-tau181, and alpha-synuclein levels with clinical features of drug-naive patients with early Parkinson disease. JAMA Neurol 2013, 70:1277-1287.
25. Chiaravalloti A., Stefani A., Fiorentini A., Lacanfora A., Stanzione P., Schillaci O. Do CSF levels of t-Tau, p-Tau and beta1-42 amyloid correlate with dopaminergic system impairment in patients with a clinical diagnosis of Parkinson disease? A (123)I-FP-CIT study in the early stages of the disease. Eur J Nucl Med Mol Imaging 2014, 41:2137-2143.
26. Vranova H.P., Henykova E., Kaiserova M., Mensikova K., Vastik M., Mares J., et al. Tau protein, beta-amyloid(1)(-)(4)(2) and clusterin CSF levels in the differential diagnosis of parkinsonian syndrome with dementia. JNeurol Sci 2014, 343:120-124.
27. Parnetti L., Farotti L., Eusebi P., Chiasserini D., De Carlo C., Giannandrea D., et al. Differential role of CSF alpha-synuclein species, tau, and Abeta42 in Parkinson's Disease. Front Aging Neurosci 2014, 6:53.
28. Wills J., Jones J., Haggerty T., Duka V., Joyce J.N., Sidhu A. Elevated tauopathy and alpha-synuclein pathology in postmortem Parkinson's disease brains with and without dementia. Exp Neurol 2010, 225:210-218.
29. Kieburtz K., McDermott M., Como P., Growdon J., Brady J., Carter J., et al. The effect of deprenyl and tocopherol on cognitive performance in early untreated Parkinson's disease. Parkinson Study Group. Neurology 1994, 44:1756-1759.